Diese Informationen dienen ausschließlich zu Bildungszwecken. Konsultieren Sie stets einen Angehörigen der Gesundheitsberufe. Mehr erfahren

Azelastine Hydrochloride Ophthalmic Solution 0.05%

Prescription

Handelsnamen: Azelastine Hydrochloride Ophthalmic Solution 0.05%

Darreichungsform
Drops
Applikationsweg
OPHTHALMIC

About This Medication

DESCRIPTION Azelastine hydrochloride ophthalmic solution, USP 0.05% is a sterile ophthalmic solution containing azelastine hydrochloride, a relatively selective H 1 -receptor antagonist for topical administration to the eyes. Azelastine hydrochloride is a white crystalline powder with a molecular weight of 418.37. Azelastine hydrochloride is sparingly soluble in water, methanol and propylene glycol, and slightly soluble in ethanol, octanol, and glycerine. Azelastine hydrochloride is a racemic mixture with a melting point of 225°C. The chemical name for azelastine hydrochloride is (±)-1-(2H)-phthalazinone,4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride and is represented by the following chemical structure: Structural formula: C 22 H 24 ClN 3 O•HCl Each mL of azelastine hydrochloride ophthalmic solution, USP 0.05% contains: Active: 0.5 mg azelastine hydrochloride, equivalent to 0.457 mg of azelastine base; Preservative: 0.125 mg benzalkonium chloride; Inactives: disodium edetate dihydrate, hypromellose, sorbitol solution, sodium hydroxide and water for injection. It has a pH of approximately 5.0 to 6.5 and an osmolarity of approximately 271 to 312 mOsmol/L. azelastine-hydrochloride-str

Wirkstoffe

Wirkstoff Stärke
Azelastine Hydrochloride -

Indikationen und Anwendung

INDICATIONS & USAGE Azelastine hydrochloride ophthalmic solution 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.

Dosierung und Verabreichung

DOSAGE & ADMINISTRATION The recommended dose is one drop instilled into each affected eye twice a day.

Side Effects Overview

ADVERSE REACTIONS In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/stinging (approximately 30%), headaches (approximately 15%) and bitter taste (approximately 10%). The occurrence of these events was generally mild. The following events were reported in 1–10% of patients: asthma, conjunctivitis, dyspnea, eye pain, fatigue, influenza-like symptoms, pharyngitis, pruritus, rhinitis and temporary blurring. Some of these events were similar to the underlying disease being studied.

Warnhinweise und Vorsichtsmaßnahmen

Kontraindikationen

Frequently Asked Questions

INDICATIONS & USAGE Azelastine hydrochloride ophthalmic solution 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.

DOSAGE & ADMINISTRATION The recommended dose is one drop instilled into each affected eye twice a day.

WARNINGS Azelastine hydrochloride ophthalmic solution 0.05% is for ocular use only and not for injection or oral use.

CONTRAINDICATIONS Azelastine hydrochloride ophthalmic solution 0.05% is contraindicated in persons with known or suspected hypersensitivity to any of its components.

Azelastine Hydrochloride Ophthalmic Solution 0.05% is a prescription medication. You will need a valid prescription from a licensed healthcare provider.

Similar Drops Products

Browse all Drops products →

References & Data Sources

Medizinischer Haftungsausschluss

Die Informationen auf dieser Seite dienen ausschließlich zu Bildungszwecken und sollten nicht als Ersatz für professionellen ärztlichen Rat, Diagnose oder Behandlung verwendet werden.

Wenden Sie sich bei Fragen zu einem medizinischen Zustand oder einem Arzneimittel stets an Ihren Arzt oder einen anderen qualifizierten Angehörigen der Gesundheitsberufe.

Datenquellen: DailyMed (NLM), openFDA, MFDS

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.